Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

X
Trial Profile

A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIDE
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 15 Feb 2020 Results assessing association of humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T treatment in two studies (STAMP and STRIDE), presented at the 2020 Genitourinary Cancers Symposium.
    • 13 Feb 2020 Results published in the Dendreon corporation media release
    • 13 Feb 2020 According to a Dendreon corporation media release, results from STAMP and STRIDE studies assessing the association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity were presented at the 2020 ASCO Genitourinary (GU) Cancers Symposium in San Francisco.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top